Applicability of modified Glasgow Prognostic Score in the assessment of elderly patients with cancer: A pilot study

Lealdini, Viviane; Trufelli, Damila Cristina; Silva, Fernanda Borges Ferreira da; Normando, Savia Raquel Costa; Camargo, Elisa Watanabe; Matos, Leandro Luongo de; Fonseca, Fernando Luiz Affonso; Santi, Patrícia Xavier; Giglio, Auro del

doi:10.1016/j.jgo.2015.09.001

Cited by 18 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only one smaller study (n=52) has formerly investigated the relationship between frailty and GPS in older patients with cancer, and the results corroborate our findings. In that study, however, frailty was identified using the Edmonton Frail Scale (34), and mGPS was used instead of GPS. Their results demonstrated a significant correlation between mGPS and frailty.…”

Section: Discussionmentioning

confidence: 99%

Screening for frailty among older patients with cancer using blood biomarkers of inflammation

Harneshaug

Kirkhus

Benth

et al. 2019

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Screening for frailty among older patients with cancer using blood biomarkers of inflammation

Harneshaug

Kirkhus

Benth

et al. 2019

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

“…The Glasgow Prognostic score relies on inflammatory biological markers (C-reactive protein and serum Albumin) and predicts survival in advanced cancer [ 28 ]. In older patients this score was related to frailty assessed by the Edmonton frailty index [ 29 ]. The score developed in the present study was in line with the growing research on frailty assessment in older patient treated for cancer.…”

Section: Discussionmentioning

confidence: 99%

One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score

Bourdel-Marchasson

Diallo²,

Bellera

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

PurposeThe MNA (Mini Nutritional Assessment) is known as a prognosis factor in older population. We analyzed the prognostic value for one-year mortality of MNA items in older patients with cancer treated with chemotherapy as the basis of a simplified prognostic score.MethodsThe prospective derivation cohort included 606 patients older than 70 years with an indication of chemotherapy for cancers. The endpoint to predict was one-year mortality. The 18 items of the Full MNA, age, gender, weight loss, cancer origin, TNM, performance status and lymphocyte count were considered to construct the prognostic model. MNA items were analyzed with a backward step-by-step multivariate logistic regression and other items were added in a forward step-by-step regression. External validation was performed on an independent cohort of 229 patients.ResultsAt one year 266 deaths had occurred. Decreased dietary intake (p = 0.0002), decreased protein-rich food intake (p = 0.025), 3 or more prescribed drugs (p = 0.023), calf circumference <31cm (p = 0.0002), tumor origin (p<0.0001), metastatic status (p = 0.0007) and lymphocyte count <1500/mm3 (0.029) were found to be associated with 1-year mortality in the final model and were used to construct a prognostic score. The area under curve (AUC) of the score was 0.793, which was higher than the Full MNA AUC (0.706). The AUC of the score in validation cohort (229 subjects, 137 deaths) was 0.698.ConclusionKey predictors of one-year mortality included cancer cachexia clinical features, comorbidities, the origin and the advanced status of the tumor. The prognostic value of this model combining a subset of MNA items and cancer related items was better than the full MNA, thus providing a simple score to predict 1-year mortality in older patients with an indication of chemotherapy.

show abstract

“…Serum CRP levels were also associated with incident frailty in more specific subgroups, such as poor functional status and more advanced clinical stage in older patients with cancer [10] and impaired physical performance in obese older adults [11]. However, Reiner et al in a 2009 prospective study concluded that there is little evidence associating CRP levels and frailty among postmenopausal women [24].…”

Section: Frailty and Crpmentioning

confidence: 99%

C-Reactive Protein and Frailty in the Elderly: A Literature Review

et al. 2017

View full text Add to dashboard Cite

Chronic inflammation is a well-established background process in many age-related diseases. Many recent studies investigate the use of various inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6, and interleukin-1 as predictors of physical and cognitive performance among elders. The phenotype of frailty has also been associated with underlying inflammatory mechanisms. The aim of this article was to review the literature referring to the correlation of CRP serum levels and frailty in older individuals. We tried to identify all relevant publications regarding the relation of CRP as an index of frailty in the elderly and its potential use. Although many studies in the recent medical literature positively associate serum CRP levels and frailty in older individuals, some do not, and some raise some interesting questions and set the basis for future studies. The association of CRP and frailty in elder patients should be considered when clinicians interpret inflammatory biomarkers in various clinical settings in such patients. Well-designed, prospective clinical trials are warranted to better assess the role and pathophysiology of frailty in the elderly and its mechanisms as also the exact role of CRP as an inflammatory marker and as a prognostic index in this syndrome.

show abstract

Applicability of modified Glasgow Prognostic Score in the assessment of elderly patients with cancer: A pilot study

Cited by 18 publications

References 17 publications

Screening for frailty among older patients with cancer using blood biomarkers of inflammation

Screening for frailty among older patients with cancer using blood biomarkers of inflammation

One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score

C-Reactive Protein and Frailty in the Elderly: A Literature Review

Contact Info

Product

Resources

About